Dementia Disease Articles & Analysis
30 news found
OLX-07010 would potentially fill a significant unmet need with a disease-modifying drug that, if successful, will have a tremendous impact on patient outcomes and reduce the burden on caregivers and society. “The issuance of the ‘766 patent supports our continued work aimed at blocking tau self-association to prevent downstream damage associated with ...
“There is a significant need in the field of neurodegenerative diseases for novel treatment strategies, specifically solutions that are cost-effective and globally scalable,” said Bill Erhardt, M.D., Chief Medical Officer of Oligomerix. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's Disease (CTAD) ...
The technology is designed to advance treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the blood-brain barrier at the top of the nasal cavity. Led by a team of experienced entrepreneurs with ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for ...
” “The prevalence of AD [Alzheimer’s disease] is increasing worldwide," said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix. “There remains an urgent need for disease-modifying drugs for AD that are safe and efficacious, cost-effective and easy to administer. ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference ...
Private investors can now invest in a company aiming to disrupt and transform a $1.3 trillion dementia market alone while benefiting millions living with neurodegenerative diseases. Diseases like Dementia and Alzheimer’s afflict millions of people across the globe, while over 1 billion people worldwide – 1 in 6 ...
Alfa Chemistry, a long-term partner for many pharmaceutical companies, universities, and research institutions, recently announced to offer donepezil, a synthetic active pharmaceutical ingredient (API) that can be used in pharmaceutical preparation for the treatment of Alzheimer's disease. API refers to the biologically active component of a drug product. ...
Published in EPMA Journal, the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker ...
Published in EPMA Journal, the study explored sex differences in Altoida’s digital cognitive assessment platform in a sample of 568 subjects consisting of a clinical dataset (mild cognitive impairment and dementia due to Alzheimer’s Disease) and a healthy population. The study results found that a biological sex classifier built on digital biomarker ...
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device technology, Kurve Therapeutics is paving the way for revolutionary clinical success in treating complex CNS disorders including Alzheimer’s disease, cognitive aging, Lewy body dementia, and Parkinson’s ...
Globally, Alzheimer's disease and related dementias (ADRD) affect 47 million people, with cases staggeringly expected to double in the next 20 years. ...
About TRANQUILITY II and III Initiated in December of 2021, TRANQUILITY II and III are pivotal Phase 3 trials evaluating BXCL501 for the acute treatment of agitation in patients with Alzheimer’s disease. The trials expand the evaluation of patients who experience agitation across diverse medical settings and across the range of dementia severity. ...
The new trial is double-blinded, randomized, and placebo-controlled, and is designed to evaluate single versus multiple doses of Lomecel-B for mild Alzheimer’s disease. The major findings of the Phase 1 study as reported in Alzheimer’s & Dementia are as follows: The primary endpoint -- safety -- was met. ...
Ariana Pharma, the eXplainable Artificial Intelligence clinical development Company, announced today the presentation of Phase 2 clinical biomarker data from the ANAVEX2-73-PDD-001 Parkinson’s Disease Dementia (PDD) study at the AD/PD 2022 International Conference. ...
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched a new application for its miniscope-based platforms to investigate neuronal activity and blood flow simultaneously, a novel research method that may prove critical to studying neurovascular dynamics in the context of aging, dementia, stroke and other ...
Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease detection, announces the closing of an up to US$2.1M ...
Brain MRI scans are currently used to rule out other neurodegenerative diseases rather than directly diagnose the cause of dementia and do not help in early diagnosis. This project, led by Oxford Brain Diagnostics and Dr Nakajima, will gather real world MRI patient data, and will use CDM analysis, based on changes at the cellular level, to assess ...
” “Aggregation of tau is highly associated with the progression of neurodegenerative disorders, including Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy,” said James Moe, Ph.D., MBA, President and CEO of Oligomerix. ...